Why biosimilars are being held back in the US
No biosimilar producers have made use of an accelerated US approval pathway introduced in 2010, and now the first case has found against a biosimilar for Enbrel. George Yu and Jason Harp explain where this leaves the industry
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
